Cardiovascular DiseaseWHHNCT02017470
A Culture-Centered Approach to Promoting Women's Heart Health in Singapore
A study testing Gender-tailored women's heart health outpatient programme in people with Cardiovascular Disease, run by National University Hospital, Singapore at 1 site in Singapore.
Trial summary
This research focuses on health needs, constructed meanings of health, and meaningful health promotion tactics among women who are heart disease patients. Women with heart disease are considered as a highly vulnerable group for cardiovascular disease-related deaths in Singapore. Read more about this study
- Who is it for?
- Ages 21 years and older, women only
- Conditions the study is for
- Cardiovascular Disease
- What is being tested?
- Gender-tailored women's heart health outpatient programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 300 participants
- Where
- 1 siteSingapore
- Study dates
- Sep 2013to Aug 2015
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 21 years and older
- Women only
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- women aged >21
- consecutive women admitted to NUH for general cardiology problems
- women patients attending general cardiology clinics
Who cannot join
- male patients
- Women requiring sub-specialty care (eg valve clinic, pulmonary hypertension clinic, congenital heart clinic)
Trial locations and contacts
1 site in 1 country.
About this study
This research focuses on health needs, constructed meanings of health, and meaningful health promotion tactics among women who are heart disease patients. Women with heart disease are considered as a highly vulnerable group for cardiovascular disease-related deaths in Singapore. Because the culture-centered approach has previously demonstrated that community-driven participatory processes of the Culture-Centered Approach (CCA) foster positive changes in health outcomes, this project highlights involvement of community members in developing effective health promotion regarding heart health. Rather than relying solely on interventions created by outside experts, The investigators aim to engage in Heart Health promotion that is meaningful through the involvement of these community members in processes of change.
Thus, the investigators seek to engage these women who are heart disease patients in developing a heart health intervention that is beneficial to them. Through in-depth interviews, focus groups, the formation of advisory boards, and community-wide dialogue workshops led by these women, the investigators seek to identify specific heart health promoting strategies and tactics that are meaningful to the lived experiences of the women. As part of the overall solution, this project will work alongside the Women's Heart Health Clinic to create training materials and disseminate findings based on our analysis.
Read more
Methodology:
As far as the methodology, the investigators are using the Culture-Centered Approach (CCA) as well as using biomedical measures for evaluation. First, an advisory board will be formed to inform each step of our methodology and data analysis. First, the investigators will randomize one group of patients into the control group and one group into the experimental group. The investigators will conduct baseline measures for both groups. For the control group, the investigators will measure biomedical data at 3 times (3 months, 6 months, and 12 months). For the experimental group, the investigators will create advisory board that will consist of approx. 4 physicians and 6 patients. In-depth interviews will be conducted with women who have experienced CVD and who live in Singapore. Each interview will last a maximum of 90 minutes. Interviewees will be asked questions about how they understand health, their health experiences, and the obstacles they face in accessing health care in Singapore. Data from the interviews will be analyzed with the advisory board and will be used to guide discussion for the focus groups of women in the experimental group.
Focus group sessions, each lasting a maximum of 90 minutes, will be conducted with the patients in the experimental group. In each session, the participants will collectively develop potential solutions for the issues that emerged during the earlier interviews.During the one-year period of study, a participant in the experimental group can participate in one or many of the one-on-one interviews, focus groups, or other activities planned based on the feedback of the participants. Based on the information given in the interviews, advisory board meetings, and focus groups, an intervention will be designed and carried out for the experimental group. This group will also be evaluated at 3 time points (3 months, 6 months, and 12 months) in addition to baseline.
Read the detailed description
The investigators are proposing a randomized clinical and social scientific trial comparing outcomes among women with cardiovascular disease into 2 treatment groups: (1) conventional general cardiology outpatient programme; (2) gender-tailored women's heart health outpatient programme consisting of general cardiologist, advanced practice nurse, dietician, physiotherapist and occupational therapist. Participants will include consecutive women admitted to NUH for general cardiology problems and those attending general cardiology clinics. Women requiring sub-specialty care (eg valve clinic, pulmonary hypertension clinic, congenital heart clinic) will be excluded. The investigators will randomly assign 150 women to a control group (where only the biomedical variables will be measured throughout the course of a year's time) and 150 to an experimental group (where the biomedical variables will be measured in addition to the participants' involvement in interviews, focus groups, and prospective workshops based on expressed needs). Randomization will occur through the consent process and after the participant is assigned to a group, the full involvement will be explained. If randomized into the experimental group, the participant will be asked to give consent for participation in one-on-one interviewing, focus group discussions, and the forthcoming health promotion strategies that are developed based on the data collected. There will be minimal risk involved in all of these intervention components since the investigators are involving our participants throughout the development process for any future intervention.
In order to develop the cultured-centred approach/processes for the women heart health programme, the investigators will begin by forming an advisory board comprising of the women patients, nurses, as well as providers. The advisory board will comprise of 8 members (4 patients, 2 nurses, 2 doctors). The advisory board will meet in the first month of the project and will subsequently meet every two months. Based on the inputs of the advisory board and the objectives established by the board, the research team will develop a design for conducting in-depth interviews with 20 patients (each in-depth interview will take 60 to 90 minutes). The interviews will take place from month 2 to month 4. The advisory team will then analyze interview data and in collaboration with NUS Communication and New Media design team, materialized health-promoting strategies into workshops, to be conducted as part of the intervention programme. Additionally, on the basis of the interview data six workshops will be conducted in groups of 4 to develop health promoting strategies and tactics. The NUS Communication and New Media (CNM) design team will collaborate with the workshop participants to develop and implement the tactics. The workshops and material development will take place in months 4 through month 6 of the project.
Once the strategies and tactics have been developed, a baseline survey will be conducted with 150 women in the CCA experimental group and 150 women in the control group. For the experimental group only, we will be conducting semi-structured short interviews. Additionally the following clinical assessments will occur for both the experimental and control groups at baseline and the 12 month visit: change in cardiovascular risk markers (lipids, fasting glucose, waist circumference, body-mass-index, blood pressure, hs-CRP, NT-proBNP, body fat analysis), vascular reactivity (endoPAT), and arterial stiffness measurement, quality of life (SF-36 Health Survey), depression (Center for Epidemiological Studies Depression Scale) and Duke activity status index. The patients' cardiovascular risk markers (Cr, Hba1C, Lipid panel or any other routing blood tests depending on physician), ordered as part of standard care will be recorded as well. Patients will be followed for 12 months for recurrent hospitalizations and deaths. Once the participants join the study, if randomized into the experimental group, they will be required to participate in one of the following activities: one-on-one interview, focus group, or joining the advisory board. The control group will only participate in the clinical assessments and a baseline interview (administration of questionnaires).
The investigators believe that health interventions should be developed from a grassroots approach incorporating the opinions and advice of the target population themselves. For the experimental group, they will be participating in the development of a heart health intervention based by sharing their experiences through our interviews, focus groups, and advisory board. The investigators believe that focusing on the voices and expertise of the population to develop an effective intervention will result in improved health outcomes for our experimental group. In order to understand to what extent, the investigators plan to compare both the biomedical and social scientific measures of the experimental group to the control group. Any intervention materials will of course be made available to the control group after the study is complete.
- Conditions
- Cardiovascular Disease
- Being tested
- Gender-tailored women's heart health outpatient programme
- Keywords
- Women Heart Health, Cardiovascular Disease, focus group, advisory board, one-on-one interview
- Medical subject headings
- Cardiovascular Diseases
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Gender-tailored women's heart health outpatient programmeOther
| Study group | Role | What they receive |
|---|---|---|
| Gender-tailored women's heart health outpatient programme | Experimental | The programme consists of general cardiologist, advanced practice nurse, dietician, physiotherapist and occupational therapist. The participant will be asked to participate in one-on-one interviewing, focus group discussions, and the forthcoming health promotion strategies that are developed based on the data collected Receives: Other: Gender-tailored women's heart health outpatient programme |
| Conventional general cardiology outpatient programme | No intervention | Not described |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change in cardiovascular risk markers
lipids, fasting glucose, Hba1C, body-mass-index and blood pressure
Measured: 12 months
Secondary outcomes (3)
Changes in quality of life
Measured: 12 months
Changes in depression and activity status
Measured: 12 months
Changes in cardiac overload and highly sensitive C reactive protein
Measured: 12 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted20 Dec 2013 (estimated)
- Study startSep 2013
- Primary completionJun 2015 (estimated)
- Study completionAug 2015 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Cardiovascular DiseaseStudies of the same condition, open and under way.
- More trials run by National University Hospital, SingaporeThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Health services research
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 300 participants (estimated)
Sponsor and investigators
- Lead sponsor
- National University Hospital, Singapore
- Sponsor type
- University, hospital or other
- Collaborators
- National University of Singapore
- Responsible party
- Sponsor
- Investigators
- Low Ting Ting, Principal investigator, National University Heart Centre, SingaporeMohan Jyoti Dutta, Principal investigator, Center for Culture-Centered Approach to Research and Evaluation
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02017470
- Sponsor's protocol ID
- DSRB:2013/00088
- Acronym
- WHH
- Status last verified
- Nov 2014
- First submitted
- 25 Oct 2013
- Last updated
- 21 Nov 2014
- Results posted
- No
- Data monitoring committee
- No
Publications
Low TT, Chan SP, Wai SH, Ang Z, Kyu K, Lee KY, Ching A, Comer S, Tan NQP, Thong EGHE, Nang T, Dutta M, Lam CSP. The women's heart health programme: a pilot trial of sex-specific cardiovascular management. BMC Womens Health. 2018 Apr 16;18(1):56. doi: 10.1186/s12905-018-0548-6.
PubMed 29661196
Study at a glance
From the registry record, last updated by the sponsor on 21 Nov 2014. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Culture-Centered Approach to Promoting Women's Heart Health in Singapore
- ClinicalTrials.gov ID
- NCT02017470
- Acronym / sponsor ID
- WHH / DSRB:2013/00088
- Conditions
- Cardiovascular Disease
- Keywords
- Women Heart Health, Cardiovascular Disease, focus group, advisory board, one-on-one interview
- Study type
- Interventional
- Recruitment status
- Unknown status
- Enrolment
- 300 participants (estimated)
- Lead sponsor
- National University Hospital, SingaporeUniversity, hospital or other
- Collaborators
- National University of Singapore
- Study start
- Sep 2013
- Primary completion
- Jun 2015 (estimated)
- Study completion
- Aug 2015 (estimated)
- First posted
- 20 Dec 2013 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This research focuses on health needs, constructed meanings of health, and meaningful health promotion tactics among women who are heart disease patients. Women with heart disease are considered as a highly vulnerable group for cardiovascular disease-related deaths in Singapore. Because the culture-centered approach has previously demonstrated that community-driven participatory processes of the Culture-Centered Approach (CCA) foster positive changes in health outcomes, this project highlights involvement of community members in developing effective health promotion regarding heart health. Rather than relying solely on interventions created by outside experts, The investigators aim to engage in Heart Health promotion that is meaningful through the involvement of these community members in processes of change.
Thus, the investigators seek to engage these women who are heart disease patients in developing a heart health intervention that is beneficial to them. Through in-depth interviews, focus groups, the formation of advisory boards, and community-wide dialogue workshops led by these women, the investigators seek to identify specific heart health promoting strategies and tactics that are meaningful to the lived experiences of the women. As part of the overall solution, this project will work alongside the Women's Heart Health Clinic to create training materials and disseminate findings based on our analysis.
Methodology:
As far as the methodology, the investigators are using the Culture-Centered Approach (CCA) as well as using biomedical measures for evaluation. First, an advisory board will be formed to inform each step of our methodology and data analysis. First, the investigators will randomize one group of patients into the control group and one group into the experimental group. The investigators will conduct baseline measures for both groups. For the control group, the investigators will measure biomedical data at 3 times (3 months, 6 months, and 12 months). For the experimental group, the investigators will create advisory board that will consist of approx. 4 physicians and 6 patients. In-depth interviews will be conducted with women who have experienced CVD and who live in Singapore. Each interview will last a maximum of 90 minutes. Interviewees will be asked questions about how they understand health, their health experiences, and the obstacles they face in accessing health care in Singapore. Data from the interviews will be analyzed with the advisory board and will be used to guide discussion for the focus groups of women in the experimental group.
Focus group sessions, each lasting a maximum of 90 minutes, will be conducted with the patients in the experimental group. In each session, the participants will collectively develop potential solutions for the issues that emerged during the earlier interviews.During the one-year period of study, a participant in the experimental group can participate in one or many of the one-on-one interviews, focus groups, or other activities planned based on the feedback of the participants. Based on the information given in the interviews, advisory board meetings, and focus groups, an intervention will be designed and carried out for the experimental group. This group will also be evaluated at 3 time points (3 months, 6 months, and 12 months) in addition to baseline.
Detailed description
The investigators are proposing a randomized clinical and social scientific trial comparing outcomes among women with cardiovascular disease into 2 treatment groups: (1) conventional general cardiology outpatient programme; (2) gender-tailored women's heart health outpatient programme consisting of general cardiologist, advanced practice nurse, dietician, physiotherapist and occupational therapist. Participants will include consecutive women admitted to NUH for general cardiology problems and those attending general cardiology clinics. Women requiring sub-specialty care (eg valve clinic, pulmonary hypertension clinic, congenital heart clinic) will be excluded. The investigators will randomly assign 150 women to a control group (where only the biomedical variables will be measured throughout the course of a year's time) and 150 to an experimental group (where the biomedical variables will be measured in addition to the participants' involvement in interviews, focus groups, and prospective workshops based on expressed needs). Randomization will occur through the consent process and after the participant is assigned to a group, the full involvement will be explained. If randomized into the experimental group, the participant will be asked to give consent for participation in one-on-one interviewing, focus group discussions, and the forthcoming health promotion strategies that are developed based on the data collected. There will be minimal risk involved in all of these intervention components since the investigators are involving our participants throughout the development process for any future intervention.
In order to develop the cultured-centred approach/processes for the women heart health programme, the investigators will begin by forming an advisory board comprising of the women patients, nurses, as well as providers. The advisory board will comprise of 8 members (4 patients, 2 nurses, 2 doctors). The advisory board will meet in the first month of the project and will subsequently meet every two months. Based on the inputs of the advisory board and the objectives established by the board, the research team will develop a design for conducting in-depth interviews with 20 patients (each in-depth interview will take 60 to 90 minutes). The interviews will take place from month 2 to month 4. The advisory team will then analyze interview data and in collaboration with NUS Communication and New Media design team, materialized health-promoting strategies into workshops, to be conducted as part of the intervention programme. Additionally, on the basis of the interview data six workshops will be conducted in groups of 4 to develop health promoting strategies and tactics. The NUS Communication and New Media (CNM) design team will collaborate with the workshop participants to develop and implement the tactics. The workshops and material development will take place in months 4 through month 6 of the project.
Once the strategies and tactics have been developed, a baseline survey will be conducted with 150 women in the CCA experimental group and 150 women in the control group. For the experimental group only, we will be conducting semi-structured short interviews. Additionally the following clinical assessments will occur for both the experimental and control groups at baseline and the 12 month visit: change in cardiovascular risk markers (lipids, fasting glucose, waist circumference, body-mass-index, blood pressure, hs-CRP, NT-proBNP, body fat analysis), vascular reactivity (endoPAT), and arterial stiffness measurement, quality of life (SF-36 Health Survey), depression (Center for Epidemiological Studies Depression Scale) and Duke activity status index. The patients' cardiovascular risk markers (Cr, Hba1C, Lipid panel or any other routing blood tests depending on physician), ordered as part of standard care will be recorded as well. Patients will be followed for 12 months for recurrent hospitalizations and deaths. Once the participants join the study, if randomized into the experimental group, they will be required to participate in one of the following activities: one-on-one interview, focus group, or joining the advisory board. The control group will only participate in the clinical assessments and a baseline interview (administration of questionnaires).
The investigators believe that health interventions should be developed from a grassroots approach incorporating the opinions and advice of the target population themselves. For the experimental group, they will be participating in the development of a heart health intervention based by sharing their experiences through our interviews, focus groups, and advisory board. The investigators believe that focusing on the voices and expertise of the population to develop an effective intervention will result in improved health outcomes for our experimental group. In order to understand to what extent, the investigators plan to compare both the biomedical and social scientific measures of the experimental group to the control group. Any intervention materials will of course be made available to the control group after the study is complete.
Study design
- Primary purpose
- Health services research
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Gender-tailored women's heart health outpatient programme | Experimental | Other: Gender-tailored women's heart health outpatient programmeThe programme consists of general cardiologist, advanced practice nurse, dietician, physiotherapist and occupational therapist. The participant will be asked to participate in one-on-one interviewing, focus group discussions, and the forthcoming health promotion strategies that are developed based on the data collected |
| Conventional general cardiology outpatient programme | No intervention | – |
Who may qualify
- Ages
- 21 years and older
- Sex
- Female only
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (3 listed)
- women aged >21
- consecutive women admitted to NUH for general cardiology problems
- women patients attending general cardiology clinics
Key exclusion criteria (2 listed)
- male patients
- Women requiring sub-specialty care (eg valve clinic, pulmonary hypertension clinic, congenital heart clinic)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Gender-tailored women's heart health outpatient programme | Other | Gender-tailored women's heart health outpatient programme |
Primary outcome
Change in cardiovascular risk markers
Time frame: 12 months
lipids, fasting glucose, Hba1C, body-mass-index and blood pressure
3 secondary outcomes
Changes in quality of life
Time frame: 12 months
Changes in depression and activity status
Time frame: 12 months
Changes in cardiac overload and highly sensitive C reactive protein
Time frame: 12 months
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 21 Nov 2014.
- Derived from this study: PubMed 29661196Low TT, Chan SP, Wai SH, Ang Z, Kyu K, Lee KY, Ching A, Comer S, Tan NQP, Thong EGHE, Nang T, Dutta M, Lam CSP. The women's heart health programme: a pilot trial of sex-specific cardiovascular management. BMC Womens Health. 2018 Apr 16;18(1):56. doi: 10.1186/s12905-018-0548-6.
Related trials for Cardiovascular Disease
Active, not recruitingPhase 3
ENDOTHELION Study Group: Effect of Bosentan in NAION Patients
Ischemic Optic Neuropathy
Active, not recruiting
Digital Reinforcement of Motivational Interviewing Micro-Skills Among Primary Care Healthcare Professionals
Hypertension (Without Type 2 Diabetes Mellitus)
Not yet recruitingPhase 2
Study of YKST02 in Adults With Relapsed or Refractory Multiple Myeloma
Relapsed or Refractory Multiple Myeloma (RRMM)
RecruitingPhase 2
Engaging T-cells to Eliminate MRD in Newly Diagnosed Myeloma Optimizing Response With Talquetmab and Teclistamab (ROTATE)
Multiple Myeloma
Recruiting
PAW-Hydrogel for Chronic Wound Healing
Diabetic Foot Ulcer (DFU), Pressure Ulcer (PU)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Low Ting Ting principal investigator
National University Heart Centre, Singapore
Mohan Jyoti Dutta principal investigator
Center for Culture-Centered Approach to Research and Evaluation
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Gender-tailored women's heart health outpatient programme in people with Cardiovascular Disease, run by National University Hospital, Singapore at 1 site in Singapore.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 21 Nov 2014. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Singapore. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change in cardiovascular risk markers (time frame: 12 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT02017470, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 21 Nov 2014.